-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66

Benzinga·10/22/2026 09:35:40
Listen to the news
BMO Capital analyst David Lebowitz upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and raises the price target from $54 to $66.